MRM Health, a biopharmaceutical company in the clinical stage, has received approval from regulatory and ethics committees to commence an observational cross-sectional clinical trial. This trial aims to identify specific microbial and metabolic patterns associated with Parkinson's disease (PD) in the small intestine microbiome. Collaborating with Nimble Sciences and the University of Calgary in Canada, the study plans to enroll up to 100 subjects, including a cohort of healthy volunteers matched for age. Led by Dr. Davide Martino at the Calgary Parkinson's Disease Research Initiative (CaPRI), the trial is registered at Clinicaltrials.gov under number NCT06003608.

Utilizing its proprietary CORAL® technology, MRM Health is developing consortium therapeutics comprising well-characterized commensal strains to enhance efficacy and resilience. Their manufacturing platform enables the production of complete consortiums as a single drug substance, addressing previous limitations in microbiome therapies. Positive results from a Phase 2a clinical trial of MH002 in ulcerative colitis, along with ongoing trials in pouchitis, highlight the potential of MRM Health's approach. Additionally, preclinical programs in autoimmune and metabolic diseases are being pursued through a partnership with IFF Nutrition Biosciences.

CEO of MRM Health, Sam Posemier, expresses excitement about collaborating with Nimble Sciences and CaPRI. He highlights the innovative SIMBA capsule for collecting small intestinal contents, anticipating unique insights into the relationship between small intestinal microbiome composition and Parkinson's disease pathophysiology.

Dr. Davide Martino, lead investigator on the trial, emphasizes the urgent need for safe and effective Parkinson's disease treatments and welcomes new disease-modifying therapies. He hopes this observational study will generate hypotheses impacting Parkinson's disease pathophysiology and lead to the development of disease-modifying therapies.

Sabina Brewman, CEO of Nimble Science, expresses confidence in the SIMBA system's ability to collect valuable data on the small intestinal microbiome in people with Parkinson's disease. Collaboration with MIT will enhance the integration of 'omics data' with the multi-omics data obtained from the SIMBA capsule.

The SIMBA system is a non-invasive, ingestible capsule designed to sample small intestinal contents. Developed by Nimble Science, the capsules have shown promise in previous studies.

Parkinson's disease is a progressive, irreversible brain disorder characterized by involuntary movements, including tremors, stiffness, and impaired balance and coordination. Current treatments focus on symptom management, highlighting the need for new disease-modifying therapies to improve patient outcomes.

 

Source: businesswire.com

Report Abuse